EC Number   |
Inhibitors |
Structure |
|---|
   3.4.21.B45 | ACTG9 |
synthetic inhibitor |
 |
| 3.4.21.B45 | alpha1-Aantichymotrypsin |
forms covalent complex with hK14 |
|
| 3.4.21.B45 | alpha1-antitrypsin |
forms covalent complex with hK14 |
|
| 3.4.21.B45 | HAI-1A |
no inhibition of KLK14 up to equimolar concentrations (5 nm) of enzyme and inhibitor. As the reaction shifts to containing excess inhibitor, KLK14 is mildly inhibited, with inhibition of 35% obtained when HAI-1A is present at 10fold excess over protease |
|
| 3.4.21.B45 | HAI-1B |
no inhibition of KLK14 up to equimolar concentrations (5 nm) of enzyme and inhibitor. As the reaction shifts to containing excess inhibitor, KLK14 is mildly inhibited, with inhibition of 26% obtained when HAI-1B is present at 10fold excess over protease |
|
| 3.4.21.B45 | lympho-epithelial Kazal type inhibitor fragment D5 |
- |
|
| 3.4.21.B45 | lympho-epithelial Kazal type inhibitor fragment D8-D11 |
- |
|
| 3.4.21.B45 | lympho-epithelial Kazal type inhibitor fragment D9-D15 |
- |
|
| 3.4.21.B45 | more |
not inhibited by lympho-epithelial Kazal type inhibitor fragments D1 and D6 |
|
| 3.4.21.B45 | Spink6 |
i.e. serine protease inhibitor Kazal type 6. Selective inhibitor of kallikreins in the skin. Spink6 possesses only one typical Kazal domain. Its mRNA is expressed at low levels in several tissues and is induced during keratinocyte differentiation. Spink6 is expressed in the stratum granulosum of human skin at various anatomical localisations and in the skin appendages, including sebaceous glands and sweat glands. Spink6 expression is decreased in lesions of atopic dermatitis. Recombinant SPINK6 is inhibitory for KLK5, KLK7 and KLK14 |
|
